BAY73-4506 Probe Substrate Study

Neoplasms Clinical Trial

Official title:

A Phase I, Non-randomized Open-label Study to Evaluate the Effect of BAY73-4506 (Regorafenib) on Probe Substrates of CYP 2C9 (Warfarin), 2C19 (Omeprazole) and 3A4 (Midazolam) in a Cocktail Approach (Group A) and on a Probe Substrate of CYP 2C8 (Rosiglitazone, Group B) in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01287598
• Other study ID #: 12434
• Status: Completed
• Phase: Phase 1
• Start date: August 2, 2011
• Est. completion date: July 30, 2018

Study information

• Verified date: July 2019
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone)

• To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: July 30, 2018
• Est. primary completion date: July 3, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female and male subjects must be = 18 years at the first screening examination / visit

• ECOG Performance Status of = 2

• Histological or cytological documentation of confirmed advanced solid tumors. Subjects should have measurable or non-measurable disease according to RECIST

• Life Expectancy of at least 3 months

• Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements conducted within 14 days prior to the first study treatment:

• Hemoglobin = 9.0 g/dL

• Absolute neutrophil count (ANC) =1,500/mm3

• Platelet count = 100,000/ mm3

• Total bilirubin = 1.5 times the upper limit of normal (ULN)

• Alkaline phosphatase = 2 times ULN

• ALT and AST = 2.5 x ULN (= 5.0 x ULN for subjects with cancer involving the liver)

• Serum creatinine = 1.5 times ULN and glomerular filtration rate (GFR)= 30 ml/min/1.73 m2, according to the MDRD (Modified Diet in Renal Disease) abbreviated formula

• Lipase = 1.5 ULN

• INR and PTT = 1.5 ULN

• Subjects who are therapeutically treated with warfarin, heparin or other anticoagulants are not eligible for study participation in Group A. Subjects who are therapeutically treated with warfarin, heparin or other anticoagulants, will be allowed to participate in Group B of the study provided they meet all eligibility criteria. Close monitoring of at least weekly evaluations will be performed until INR or PTT are stable by the local standard of care.

• Recovery from previous drug/procedure-related toxicities to CTC Grade 0 or 1 levels (except for alopecia), or to baseline preceding the prior treatment. Preexisting chemotherapy induced sensory neuropathy of CTC Grade =2 is not an exclusion criteria.

• Negative serum pregnancy test must be obtained within 7 days prior to the start of treatment in women of childbearing potential. Negative results must be available prior to study treatment.

• Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib.

• An adequate contraception includes the use of condoms or a vasectomy, hormonal contraception with implants or combined PO contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined PO contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy, use of condoms or a vasectomy.

Exclusion Criteria:

• History of cardiac disease: Congestive heart failure (New York Heart Association, NYHA, Class III or IV) or active coronary artery disease (unstable angina [angina symptoms at rest] or new-onset angina [began within the last 3 months] or myocardial infarction within the past 6 months). Treatment with Type 1A or 3 anti-arrhythmics, such as Quinidine, Procainamide, Amiodarone, or Sotalol are not permitted. ß-Blockers and digoxin are permitted.

• Left ventricular ejection fraction (LVEF) < 50% or below the LLN for the institution (whichever is higher).

• Subjects with pheochromocytoma

• Dehydration NCI-CTCAE, version 4, Grade > 1

• Uncontrolled hypertension (failure of diastolic blood pressure to fall to or below 90 mmHg or systolic blood pressure to fall to or below 140 mmHg with or without the use of antihypertensive drugs). At screening, subjects with history of hypertension should be on a stable anti-hypertensive treatment for at least 7 days prior to the first dose of study drug.

• Patients with known allergy to any of the study drug(s) to be administered, including known severe allergies, non-allergic drug reactions, or multiple drug allergies to any of the study drug(s) to be administered. This is also includes hypersensitivity to any of the compounds or excipients that will be administered to the study subject, specifically regorafenib, and warfarin, omeprazole and midazolam for subjects in Group A, or rosiglitazone for subjects in Group B.

• Subjects with arterial or venous thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism within 6 months before the start of study medication.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Regorafenib (Stivarga, BAY73-4506)
BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
• Warfarin
CYP 2C9 (warfarin) at Cycle 1
• Omeprazole
CYP 2C19 (omeprazole) at Cycle 1
• Midazolam
CYP 3A4 (midazolam) at Cycle 1
• Rosiglitazone
CYP2C8 (rosiglitazone) at Cycle 1

Locations

Country	Name	City	State
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Juravinski Cancer Centre	Hamilton	Ontario
Canada	Sir Mortimer B. Davis Jewish General Hospital	Montreal	Quebec
Canada	British Columbia Cancer Agency-Vancouver Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics of probe substrates (AUC, Cmax, etc.)		Approximately 6 weeks
Secondary	Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)		Up to 3 years or longer if indicated
Secondary	Adverse event collection		Up to 3 years or longer if indicated

External Links

•   Click here to find results for studies related to Bayer Healthcare products.